Effects of four traditional Chinese medicines on the pharmacokinetics of simvastatin

References

• Abad MJ, Bedoya LM, Bermejo P. (2010). An update on drug interactions with the herbal medicine Ginkgo biloba. Curr Drug Metab 11:171–81
   PubMed Web of Science ®Google Scholar
• CCEP Experts Group. (2014). Advice for prevention and treatment of dyslipidemia, China Cholesterol Education Program in 2014. Chin Circ J 29:410–11 (in Chinese)
   Google Scholar
• Chan P, Huang TY, Tomlinson B, et al. (1997). Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol 37:496–501
   PubMed Web of Science ®Google Scholar
• Chang JJ, Chen TH, Chan P, et al. (2001). The in vitro inhibitory effect of tannin derivatives on 3-hydroxy-3-methylglutaryl-coenzyme a reductase on vero cells. Pharmacology 62:224–8
   PubMed Web of Science ®Google Scholar
• Chen TH, Liu JC, Chang JJ, et al. (2001). The in vitro inhibitory effect of flavonoid astilbin on 3-hydroxy-3-methylglutaryl coenzyme A reductase on vero cells. Zhonghua Yi Xue Za Zhi (Taipei) 64:382–7
   PubMedGoogle Scholar
• Cheng H, Rogers JD, Sweany AE, et al. (1992). Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin. Pharm Res 9:1629–33
   PubMed Web of Science ®Google Scholar
• Cheng ZN, Zhang BK, Li HD, et al. (2002). The inhibit effect of Zhi-Ke-Ju-Hong on CYP3A4 and CYP1A2 activity. Chin Clin Pharma 18:215–18 (in Chinese)
   Google Scholar
• Chung N, Cho SY, Choi DH, et al. (2001). STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Clin Ther 23:858–70
   PubMed Web of Science ®Google Scholar
• Dai LL, Fan L, Wu HZ, et al. (2013). Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects. Xenobiotica 43:862–7
   PubMed Web of Science ®Google Scholar
• Dong HY, Shao JW, Chen JF, et al. (2008). Transcriptional regulation of cytochrome P450 3A4 by four kinds of traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi 33:1014–17 (in Chinese)
   PubMedGoogle Scholar
• Duan JA, Su SL, Fan XS, et al. (2012). Explore the action patterns and mechanisms of traditional Chinese medicine incompatibility of Qi-Qing antagonism and mutual inhibition/restraint based on drug interaction. World Sci Tec/Mode Tradit Chin Med Mater Med 14:1547–52 (in Chinese)
   Google Scholar
• Elsby R, Hilgendorf C, Fenner K. (2012). Understanding the critical disposition pathways of statins to assess drug–drug interaction risk during drug development: it's not just about OATP1B1. Clin Pharmacol Ther 92:584–98
   PubMed Web of Science ®Google Scholar
• Fasinu PS, Bouic PJ, Rosenkranz B. (2014). The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb–drug interaction. Afr J Tradit Complement Altern Med 11:54–61
   PubMed Web of Science ®Google Scholar
• Foster BC, Vandenhoek S, Tang R, et al. (2002). Effect of several Chinese natural health products of human cytochrome P450 metabolism. J Pharm Pharm Sci 5:185–9
   PubMed Web of Science ®Google Scholar
• Fugh-Berman A, Ernst E. (2001). Herb–drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52:587–95
   PubMed Web of Science ®Google Scholar
• Fujita K. (2004). Food–drug interactions via human cytochrome P450 3A (CYP3A). Drug Metabol Drug Interact 20:195–217
   PubMedGoogle Scholar
• Hu LM, Jiang M, Wang SX, et al. (2005). Impact of Borneolum Syntheticum on contents of CYP450 in rat liver and expression of CYP3A1 mRNA. Tianjin J Tradit Chin Med 4:284–6 [in Chinese]
   Google Scholar
• Izzo AA, Di Carlo G, Borrelli F, Ernst E. (2005). Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 98:1–14
   PubMed Web of Science ®Google Scholar
• Jeong HU, Kong TY, Kwon SS, et al. (2013). Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 18:10681–93
   PubMed Web of Science ®Google Scholar
• Jin SJ, Bae KS, Cho SH, et al. (2014). Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics. Pharm Res 31:1801–12
   PubMed Web of Science ®Google Scholar
• Kimura Y, Ito H, Ohnishi R, Hatano T. (2010). Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 48:429–35
   PubMed Web of Science ®Google Scholar
• Lau C, Mooiman KD, Maas-Bakker RF, et al. (2013). Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol 149:543–9
   PubMed Web of Science ®Google Scholar
• Lawes CM, Rodgers A, Bennett DA, et al. (2003). Blood pressure and cardiovascular disease in the Asia Pacific region. Hypertens J 21:707–16
   PubMed Web of Science ®Google Scholar
• Le Goff-Klein N, Koffel JC, Jung L, Ubeaud G. (2003). In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice. Eur J Pharm Sci 18:31–5
   PubMed Web of Science ®Google Scholar
• Liu JC, Chan P, Hsu FL, et al. (2002). The in vitro inhibitory effects of crude extracts of traditional Chinese herbs on 3-hydroxy-3-methylglutaryl-coenzyme A reductase on vero cells. Am J Chin Med 30:629–36
   PubMed Web of Science ®Google Scholar
• Madabushi R, Frank B, Drewelow B, et al. (2006). Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62:225–33
   PubMed Web of Science ®Google Scholar
• Merkler M, Reiner Z. (2007). The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol 21:1–3
   PubMed Web of Science ®Google Scholar
• Ou XR, Wang XQ, Deng SN. (2012). Effect of different doses of simvastatin in treatment of hyperlipidemia in the elderly. Chin J Geronto 32:5147–8 (in Chinese)
   Google Scholar
• Pedersen TR, Tobert JA. (2004). Simvastatin: a review. Expert Opin Pharmacother 5:2583–96
   PubMed Web of Science ®Google Scholar
• Perk J, De Backer G, Gohlke H, et al. (2012). European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med 19:403–88
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Gorham LM, Ma B, et al. (1997). In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191–9
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Qiu Y, Mu L, et al. (2005). Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm Res 22:1101–9
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Subramanian R, Fang X, et al. (2002). Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 30:505–12
   PubMed Web of Science ®Google Scholar
• Southern Medicine Economic Research Institute, CFDA. (2012). Research report for cardiovascular Chinese patent medicine market. Southern Medicine Economic Research Institute, CFDA [Online] Available from: http://emuch.net/html/201310/6516521.html [last accessed 23 Oct 2013] (in Chinese)
   Google Scholar
• Werba JP, Giroli M, Cavalca V, et al. (2008). The effect of green tea on simvastatin tolerability. Ann Intern Med 149:286–7
   PubMed Web of Science ®Google Scholar
• Wu B, Liu P, Gao Y, Wang Y. (2011). Effect of water extract from traditional Chinese medicines Rehmannia glutinosa, Scrophularia ningpoensis, Asparagus cochinchinensis and Ophiopogon japonicus on contents of CYP450 and activities of CYP3A, CYP2E1 and CYP1A2 in rat. Zhongguo Zhong Yao Za Zhi 36:2710–14. [in Chinese]
   PubMedGoogle Scholar
• Wu BL, Liu P, Gao Y, Wang YG. (2011). Modulation effects of water extract from Ziziphus jujaba, Polygala tenuifolia and Platycodon grandiflorum on the activity and mRNA expression. Chin J Exp Tradit Med Formulae 17:235–9 (in Chinese)
   Google Scholar
• Yang YM. (2011). The effect of Angelica sinensis on the pharmacokinetic of ketoconazole in human. Changsha, China: Central South University Master’s Degree Paper (in Chinese)
   Google Scholar
• Yuan F, Chen J, Wu WJ, et al. (2010). Effects of matrine and oxymatrine on catalytic activity of cytochrome p450s in rats. Basic Clin Pharmacol Toxicol 107:906–13
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang R, Wang L, et al. (2013). Effects of an aqueous extract of Crataegus pinnatifida Bge. var. major N.E.Br. fruit on experimental atherosclerosis in rats. J Ethnopharmacol 148:563–9
   PubMed Web of Science ®Google Scholar
• Zheng YF, Bae SH, Choi EJ, et al. (2014). Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. Food Chem Toxicol 68:117–27
   PubMed Web of Science ®Google Scholar
• Zou Y, Hu D, Yang X, et al. (2003). Lipid-lowering efficacy and safety of varying doses of simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study. Chin Med J (Engl) 116:853–6
   PubMed Web of Science ®Google Scholar